ABL Bio saw the highest growth of 0.99% in patent filings and 2.99% in grants in May in Q2 2024. Compared to Q1 2024, Q2 2024 saw an increase in patent filings by 0.39% and no change in grants. GlobalData’s DataBook provides a comprehensive analysis of ABL Bio’s patent filings and grants. Buy the databook here.
Smarter leaders trust GlobalData
ABL Bio has been focused on protecting inventions in China(CN) with four publications in Q2 2024
The China(CN) Patent Office dominates the patent filings and grants with nearly 40% filings and 50% grants. The China(CN), European Patent Office(EPO), Israel(IL), and Australia(AU) patent Office are among the top ten patent offices where ABL Bio is filings its patents. Among the top granted patent authorities, ABL Bio has 50% of its grants in China(CN), 25% in Australia(AU) and 25% in South Korea(KR).
Regeneron Pharmaceuticals and Amgen could be the strongest competitors for ABL Bio
For comprehensive analysis of ABL Bio's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData patents database covers bibliographic from all 100+ patenting authorities. All patents are tagged to 18+ industries and 300+ sub-sectors based on technology classification, keywords, and associated companies. They are also tagged to various industries themes (100+) and technology domains (1800+) of focus.
Patents database further disambiguates assignee names (13m names) and associate corporate tree hierarchy in current/point in time ownerships (320k entities). GlobalData sources content directly from national patent offices on a weekly basis.
